This review summarizes the development and clinical utility of renin-angiotensin system blockers, including ACE inhibitors, ARBs, and emerging dual-action agents like vasopeptidase inhibitors, in managing cardiovascular and renal diseases.
No takes yet. Share an insight, caveat, or question.
Does not alter RAS blocker prescribing; leaves open the role of vasopeptidase inhibitors pending randomized trials.
Michel Burnier (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: